HSD67 The Burden of Systemic Glucocorticoid (GC) Use in Anti-Neutrophilic Cytoplasmic Autoantibody (ANCA)-Associated Vasculitis Patients

Quantify the amount of GC use in newly diagnosed granulomatosis with polyangiitis (GPA) and microscopic (MPA) commercially insured Medicare fee for service (FFS) populations. Using 2016-2019 Milliman proprietary commercial claims data 100% FFS Innovator Research data, GPA MPA were identified index years 2017 2018 as those at least two qualifying coded a disease ICD-10-CM code. Newly patients no claim or 12 months prior to their first 2018. Oral injectable was non-inpatient using NDC HCPCS codes. Use GCs during inpatient stays is not identifiable, such this analysis underestimates total load. The prednisolone-equivalent dose milligrams (mg) calculated by converting scripts/claims basis. We 390 70 3,719 1,168 who also had eligibility date through 18 after date. cumulative doses were: 32% 33% used 1-999 mg; 39% 1,000-4,999 25% 16% 5,000-9,999 11% 13% 10,000+ mg, respectively population. 46% 26% 29% 37% 19% 28% 6% 8% Most treated high amounts GCs. Given side-effects reported doses, report highlights need sparing therapies.